Riluzole 13C 15N2

Riluzole 13C 15N2 is a labeled version of the drug Riluzole, which is commonly used in the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurological disorder that affects nerve cells in the brain and spinal cord. Riluzole works by reducing the levels of a neurotransmitter called glutamate, which is known to cause damage to nerve cells in people with ALS. Riluzole 13C 15N2 is a stable isotope-labeled form of Riluzole that is used in pharmacokinetic studies and drug metabolism research. It is chemically identical to the non-labeled version of the drug, but it contains additional carbon-13 and nitrogen-15 isotopes that are useful for tracking the drug's absorption, distribution, metabolism, and excretion in the body. The chemical formula of Riluzole 13C 15N2 is C8H5N3O, and its molecular weight is 176.15 g/mol. The drug is a white to off-white crystalline powder that is soluble in water and ethanol. Riluzole 13C 15N2 is typically administered orally in tablet form, with dosages ranging from 50 mg to 100 mg per day, depending on the patient's age, weight, and medical history. Overall, Riluzole 13C 15N2 is an important tool for researchers studying the pharmacokinetics and metabolism of Riluzole, as well as for clinicians treating patients with ALS. Its stable isotope labeling makes it a valuable tool for tracking the drug's behavior in the body, which can help improve treatment outcomes and reduce side effects.